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INTRODUCTION AND OBJECTIVES: Patients with clinical
cT1abN0M0 renal cancers treated with radical nephrectomy (RN) or
nephron sparing surgery (NSS) occasionally have unexpected micro-
scopic invasion of renal vein and/or perirenal/sinus fat (pT3a) on final
pathological assessment. There is no data available, in this setting, to
judge if NSS might have undermined the cancer control relative to RN.
METHODS: As part of an international multi-institutional
collaboration, clinical cT1abN0M0 RCC cases that harboured pT3a
disease at final pathology were identified. Patients with multifocal,
bilateral or metastatic disease were excluded. Univariable and multi-
variable Cox regression analyses were used to test the effect of treat-
ment type (NSS vs. RN) on metastases-free survival and cancer-
specific survival rates. Bootstrapping was used to decrease the degree
of model overfitting.
RESULTS: Overall, 273 RCC patients with a clinically-defined
diagnosis of cT1abN0M0 [cT1aN0M0 (n¼107, 39.2%), cT1bN0M0
(n¼166, 60.8%)] harboured pT3a disease at final pathology. pT3a was
defined for the presence of microscopic perirenal and/or sinus fat in-
vasion (79.2%), microscopic renal vein invasion (12.7%) or both entities
(8.1%). Patients were treated with either NSS (n¼71, 26%) or RN
(n¼202, 74%). Median age was 67y (IQR 58-74). Median clinical tumor
size resulted 5cm (IQR 3.1-6.0). Fuhrman grade was 1-2 vs. 3-4 in 159
(58.2%) vs. 114 (41.8%) cases, respectively. Necrosis and sarcomatoid
features were recorded in 33% and 2% of patients, respectively. After a
mean follow-up of 53 months, metastases-free survival resulted 90.5 vs.
86.5 vs. 77.8% at 1 vs. 2 vs. 5 years after surgery. Cancer-specific
survival was 96.5 vs. 90.1 vs. 82.5%, respectively. At multivariable
analyses, clinical tumor size (HR 1.6, 95%CI 1.2-2.1, p¼0.002), high
Fuhrman grade (HR 2.3, 95%CI 1.2-4.5, p¼0.01) and presence of
sarcomatoid features (HR 4.3 95%CI 1.3-15.2, p¼0.02) resulted inde-
pendent predictors of metastatic progression. Type of surgery (NSS vs.
RN) was not an independent predictor status of either metastasis-free
survival (p¼0.4) or cancer-specific mortality (p¼0.3).
CONCLUSIONS: Utilising a large multi-institutional cohort of
RCC patients, the current study represents the first attempt to define
whether NSS might undermine cancer control when an unanticipated
pT3a disease is finally found at final pathology. In this specific scenario,
despite the presence of unexpected non-organ confined disease, NSS
does not seem to jeopardize cancer control.
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INTRODUCTION AND OBJECTIVES: The benefit of retroperi-
toneal lymph node dissection (RPLND) among patients with locallyadvanced kidney cancer and clinical lymphadenopathy (cN+) disease
remains controversial. Several studies have suggested a therapeutic
and staging benefit to performing RPLND at the time of radical ne-
phrectomy (RN). We sought to assess temporal trends in RPLND, and
to identify patient and hospital factors associated with its use among
patients with non-metastatic cN+ kidney cancer.
METHODS: Using the National Cancer Database (NCDB), we
identified patients with renal cell carcinoma (RCC) with regional lymph
node metastasis but without distant metastasis (T1-4 cN1 M0) who
underwent radical nephrectomy from 2001 to 2011. The primary
outcome was performance of concomitant RPLND at the time of RN.
Multivariable logistic regression was used to identify clinicopathologic
and hospital characteristics associated with performance of RPLND at
the time of RN. A two-sample t-test was used to compare the mean
number of lymph nodes removed by hospital type.
RESULTS: Of a total 1853 patients undergoing RN for cN+
RCC, 1444 (78%) underwent RPLND and 409 (22%) did not. Time trend
analysis showed an increase in the proportion of patients undergoing
RPLND over time, from 77% in 2001 to 82% in 2011, p¼0.001 for the
overall trend. On multivariable analysis, factors associated with RPLND
were private health insurance (OR: 2.22; 95% CI: 1.46-3.39, p<0.001)
and Medicaid (OR: 2.08; 95% CI 1.11-3.92, p¼0.02) compared to
Medicare, and treatment at an academic center compared to commu-
nity hospitals (OR: 1.59; 95% CI: 1.23-2.08, p<0.001). The mean
number of lymph nodes removed during RPLND was higher when done
at academic centers compared to community hospitals (8.1 vs. 5.0;
p<0.001).
CONCLUSIONS: Despite the growing evidence that RPLND
has a role in the surgical management of locally advanced kidney
cancer in the non-metastatic setting, a fifth of patients with clinical lymph
node metastasis are not receiving RPLND. Patients undergoing surgery
at academic centers, or those who are primarily insured by private in-
surance or Medicaid, were more likely to have more aggressive surgical
treatment. Centralizing surgery to high volume academic medical cen-
ters may increase the rates and yield of RPLND for RCC with lymph
node metastasis.
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INTRODUCTION AND OBJECTIVES: Hemostasis is critical
during robotic partial nephrectomy (RPN). Hemostatic agents (HA) are
used empirically to minimize postoperative bleeding, but supporting
evidence is lacking. We sought to assess the impact of HA on bleeding
after RPN.
METHODS: Using our retrospective database, we abstracted
data on consecutive patients treated with RPN from 2011 (after the RPN
learning curve) to 2015. In 2014, HA use for RPN was stopped due to
cost reduction measures. Patients with preoperative hemoglobin < 11
g/dL, estimated blood loss  250 ml, or intraoperative blood transfusion
were excluded to avoid confounding from chronic anemia or intra-
operative bleeding (n¼266). The outcomes were postoperative trans-
fusion and hemoglobin decline prior to transfusion or at the time of the
first follow-up visit. The associations between HA use and the outcomes
were assessed by univariate and multivariate analyses adjusting for
bleeding risk factors. Total inflation-adjusted costs in 2015 were
calculated using the US Department of Labor0s Consumer Price Index.
RESULTS: Of 550 cases, a HA was used in 214 (38.9%). Mean
number of agents used per case was 1.40.73, including 67 (12.2%),
48 (8.7%), and 45 (8.2%) cases in which cellulose, gelatin, or fibrin-
based HA were used, respectively, and 54 (9.8%) cases in which
multiple types of HA were used. Overall, 10 (1.8%) patients were
transfused postoperatively, and the median postoperative hemoglobin
decline was 2.3 g/dL (IQR 1.5-3.0). On univariate analysis, neither HA
